Fertility drug pergoveris tested in japanese and caucasian women

NCT ID NCT07269327

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed phase 1 study looked at how the fertility drug Pergoveris (a combination of two hormones, FSH and LH) is processed in the body of 24 healthy premenopausal women of Japanese or Caucasian origin. Participants took a birth control pill for about 4 weeks to suppress their natural hormones, then received a single injection of Pergoveris. The goal was to measure hormone levels in the blood and check for side effects, helping to guide future dosing in fertility treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pergoveris (follitropin alfa and lutropin alfa)

What this could lead to

If successful, this study could help doctors choose the right dose of Pergoveris for fertility treatments in women of different ethnic backgrounds.

What could go wrong

This is a very early, small study (24 healthy women) looking at drug levels, not actual fertility outcomes. Results may not apply to women with fertility issues or other ethnic groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fortrea Clinical Research Unit Ltd

    Leeds, United Kingdom